Association Members: Take Action on Drug Shortages

Visit the ASCO ACT Network

Drug Shortages Policy Recommendations

• 2018 Summit on Drug Shortages to Examine Impact on National Security and Health Care Infrastructure
• Recommendations from 2018 Summit
• 2017 Drug Shortages Roundtable
• 2017 Drug Shortages Roundtable Report

Association for Clinical Oncology Activities 

• February 6, 2024: ASCO CMO Dr. Julie Gralow's Testimony Before the House Commitee on Ways and Means 
• January 4, 2024: A Call to Action to from Health-Related Organizations to Mitigate and Prevent Drug Shortages
• December 5, 2023: ASCO Government Relations Committee Past Chair Dr. Jason Westin's Testimony Before the Senate Committee on Finance  
• September 14, 2023: ASCO Statement for the Record for the House Energy and Commerce Committee, Health Subcommittee Drug Shortages Hearing   
• August 25, 2023: ASCO Response to House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) on the Stop Drug Shortages Act Discussion Draft
• July 7, 2023: ASCO Response to Drug Shortages Request for Information (RFI) from House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) and Senate Finance Committee Ranking Member Mike Crapo (R-ID)
• June 13, 2023: ASCO CMO Dr. Julie Gralow's Testimony Before the House Energy And Commerce Committee PAHPA Hearing
• May 11, 2023: ASCO Statement for the Record for the House Energy and Commerce Committee, Oversight and Investigations Subcommittee Drug Shortages Hearing
• May 11, 2023: ASCO Statement for the Record for the House Energy and Commerce Committee PAHPA Hearing
• April 10, 2023: ASCO Testimony to the House Appropriations Committee Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Subcommittee
• March 29, 2023: ASCO Response to Senate Health, Education, Labor and Pensions Committee Pandemics All-Hazard Preparedness Act (PAHPA) Request for Information (RFI)
• March 22, 2023: ASCO Statement for the Record for Senate Homeland Security and Government Affairs Committee Hearing
• 2021: Health Groups Recommendations to Improve Supply Chain Resiliency
• April 12, 2021: Letter to Biden Administration in Response to Supply Chain Executive Order (Executive Order 14017)
• June 25, 2020: Letter to Congressional Leadership on Oncology Drug Shortages During COVID-19

Additional Resources

• White House “100 Day” Report: Supply Chain Review (including pharmaceuticals), June 2021
• FDA: Drug Shortages: Root Causes and Potential Solutions (published 2019, updated 2021)
• FDA: Report to Congress: Drug Shortages for Calendar Year 2021 (required annual report)

Answers to questions about oncology drug shortages published herein are provided by the American Society of Clinical Oncology, Inc. (“ASCO”) for voluntary, informational use by providers in the rapidly evolving drug shortage crisis. This information does not constitute medical or legal advice, is not intended for use in the diagnosis or treatment of individual conditions, does not endorse products or therapies, recommend or mandate any particular course of medical care, and is not a statement of the standard of care. New evidence may emerge between the time information is developed and when it is published or read. The information is not comprehensive or continually updated. This information is not intended to substitute for the independent professional judgment of the treating provider in the context of treating the individual patient. ASCO provides this information on an “as is” basis, and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions. Use of the information is subject to the complete ASCO website Terms of Use.